# SECTION 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY / UNDERTAKING

| 1.1 Product identifier.            |  |  |  |  |  |
|------------------------------------|--|--|--|--|--|
| Product name:                      | GNAS Mouse Monoclonal Antibody [A8F12]   |  |  |  |  |
| Product number:                    | HA601074   |  |  |  |  |
| Pure substance/mixture:            | Mixture  |  |  |  |  |
| 1.2 Relevant identified uses of t  | 1.2 Relevant identified uses of the substance or mixture and uses advised against:                         |  |  |  |  |
| Product use:                       | For research purposes only. Not for diagnostic purposes  |  |  |  |  |
| 1.3 Details of the supplier of the | e safety data sheet:   |  |  |  |  |
| Company:                           | HUABIO<br>300 Tradecenter Drive, Suite 1710<br>Woburn, MA 01801, USA<br>E-mail address: support@huabio.com |  |  |  |  |

### SECTION 2. HAZARDS IDENTIFICATION

### 2.1 Classification of the substance or mixture according to CLP No 1272 / 2008/GB CLP.

Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008.

#### 2.2 Label elements CLP No 1272/2008/GB CLP.

Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008.

#### 2.3 Other hazards.

Contains no PBT or vPvB substances according to REACH No 1907/2006.

This mixture does not contain substances with endocrine disrupting properties in accordance with the criteria laid down in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.1 Subtance:

The product is a mixture.

#### 3.2 Mixtures:

| CAS/EC No | REACH No                   | Name      | Content %         | Classification |
|-----------|----------------------------|-----------|-------------------|----------------|
| 56-81-5 / | 01-2119471987-<br>18- XXXX | Glycerine | >= 30 - < 50<br>% | Not classified |
| 200-289-5 |                            |           | 70                |                |



### SECTION 4. FIRST AID MEASURES

#### 4.1 Description of first aid measures.

| Inhalation:   | Move affected person to fresh air and keep warm and at rest in a position comfortable for breathing.   |
|---------------|--|
| Skin contact: | Wash skin with plenty of soap and water. Seek doctor if irritation persist.  |
| Eye contact:  | Remove contact lenses. Flush eyes with plenty of water for several minutes.<br>Make sure you flush under the upper and lower eyelids. If irritation continues, contact a doctor. |
| Swallow:      | Rinse mouth  |

**4.2 Most important symptoms and effects, both acute and delayed:** For more information, see Section 2.2.

**4.3 Indication of any immediate medical attention and special treatment needed:** Treat symptomatically.

### SECTION 5. FIRE FIGHTING MEASURES

5.1 Extinguishing media: Water spray, dry chemical, carbon dioxide (CO2) or chemical foam.

### Unsuitable extinguishing media:

For this substance/mixture no limitations of extinguishing agents are given.

#### 5.2 Special hazards arising from the substance or mixture:

Carbon oxides

Not combustible.

# **5.3 Advice for firefighters:** Do not enter fire area without proper protective equipment, including respiratory protection.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures:

Ensure adequate ventilation.

6.2 Environmental precautions:

See section 12 for additional environmental disclosures.

### 6.3 Methods and material for containment and cleaning up:

Avoid further leaks or spills if it is safe to do. Pick up mechanically and dispose of in suitable containers.

### 6.4 Reference to other sections:

See section 8 for information on personal protection equipment. See section 13 for disposal information.

### SECTION 7. HANDLING AND STORAGE

7.1 Precautions for safe handling:

Ensure adequate ventilation.

7.2 Conditions for safe storage, including any incompatibilities:



#### 7.3 Specific end use(s): The identified uses for this product are detailed in Section 1.2.

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1 Control parameters

| Chemical Name     | EU OEL (TWA)   | EU OEL (STEL)              | EU Skin Notation                |
|-------------------|--|----------------------------|---------------------------------|
| Glycerin 56-81-5  | None   | None                       | None                            |
|                   |  |                            |                                 |
| Chemical Name     | Austria  | Belgium (TWA)              | Czech Republic                  |
| Glycerin 56-81-5  | None   | 10 mg/m <sup>3</sup>       | 10 mg/m³ TWA                    |
|                   |  |                            | 15 mg/m <sup>3</sup> Ceiling    |
| Chemical Name     | Denmark (TWA)  | Finland OEL (TWA)          | France OEL (VME)                |
| Glycerin 56-81-5  | None   | None                       | 10 mg/m <sup>3</sup>            |
| Giyceriii 30-81-3 | None   | None                       | 10 mg/m                         |
| Chemical Name     | Germany OEL (TWA)                                      | Ireland (TWA)              | Italy OEL (TWA)                 |
|                   | 200 mg/m <sup>3</sup> exposure factor 2                | None                       | None                            |
| Glycerin 56-81-5  |  | None                       | None                            |
| Chemical Name     | Lithuania OEL (TWA)                                    | Netherlands OEL (MAC)      | Norway                          |
| Glycerin 56-81-5  | None   | None                       | None                            |
|                   | None   | None                       | None                            |
|                   |  |                            |                                 |
| Chemical Name     | Poland   | Portugal                   | Spain OEL (TWA)                 |
| Glycerin 56-81-5  | 10 mg/m³ TWA   | 10 mg/m³ TWA               | 10 mg/m <sup>3</sup>            |
|                   |  |                            |                                 |
| Chemical Name     | Sweden - Occupational Exposure<br>Limits - TLVs (LLVs) | Switzerland                | United Kingdom                  |
|                   | None   | 100 mg/m <sup>3</sup> STEL | 10 mg/m <sup>3</sup> TWA (mist) |
| Glycerin 56-81-5  |  |                            |                                 |

8.2 Exposure controls.

Appropriate technical measures:

Change contaminated clothing. Wash hands after working with substance.

General information:

Make sure that eyewash station is available.

Personal protective equipment:

Only CE-marked personal protection equipment should be used.



**Respiratory protection:** 

Not necessary.



| Hand protection: | Wear gloves. EN 374.<br>Option: Nitrile gloves: ≥120 min.<br>Thickness: ≥0.25 mm. |  |
|------------------|---|--|
| Eye protection:  | Wear tightly safety goggles. EN 166.  |  |
| Body protection: | Normal work clothing.   |  |

Measures to avoid environmental exposure:

No special precautions are necessary.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

### 9.1 Information on basic physical and chemical properties.

## **9.2 Other information:** None.

### SECTION 10. STABILITY AND REACTIVITY

- **10.1 Reactivity:** No information is available.
- **10.2 Chemical stability:** Stable under normal conditions.
- 10.3 Possibility of hazardous reactions:
- None known.
- **10.4 Conditions to avoid:** None known.
- 10.5 Incompatible materials: Strong oxidizing agents.
- 10.6 Hazardous decomposition products:

According to available information, none known.

### SECTION 11. TOXICOLOGICAL INFORMATION

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008.

| Chemical Name | Oral LD50          | Dermal LD50       | Inhalation LC5 0 |
|---------------|--------------------|-------------------|------------------|
| Glycerin      | = 12600 mg/kg Oral | > 10 g/kg(Rabbit) | >2.75mg/L(Rat)   |



| Acute toxicity:   | Oral: No date available   |
|---|---|
|   | Inhalation:No date available  |
|   | Dermal: No date available   |
| Skin corrosion/irritation:                                | No date available   |
| Serious eye<br>damage/irritation:                         | No date available   |
| Respiratory or skin sensitisation:                        | No date available   |
| Germ cell mutagenicity:                                   | No date available   |
| Carcinogenicity:  | No date available   |
| Reproductive toxicity:                                    | No date available   |
| Specific target organ toxicity - single exposure:         | No date available   |
| Specific target organ<br>toxicity - repeated<br>exposure: | No date available   |
| Aspiration hazard:  | No date available   |
| 11.2 Information on other haza                            | ırds:   |
| Endocrine disrupting propertie                            | es:<br>The product/substance has no endocrine disrupting properties.  |
| Other information:  | Ingestion May irritate the digestive system.<br>Skin contact Skin irritation.<br>Eye contact May cause severe eye damage. |



### SECTION 12. ECOLOGICAL INFORMATION

### 12.1 Toxicity:

Contains no substances known to be hazardous to the environment or not degradable in waste water treatment plants.

| Chemical Name | Toxicity to algae | Toxicity to daphnia<br>and other aquatic<br>invertebrates | Toxicity to fish  | Microtox Data     | log Pow     |
|---------------|-------------------|---|-------------------|-------------------|-------------|
| Glycerin      | No data available | No data available   | No data available | No data available | logPow-1.76 |

- 12.2 Persistence and degradability: Inherently biodegradable.
- **12.3 Bioaccumulative potential:** Material does not bioaccumulate.
- **12.4 Mobility in soil:** No information available.
- 12.5 Result of PBT and vPvB assessment: This substancee does not meet the criteria for PBT or vPvB according to regulation.
- 12.6 Endocrine disrupting properties:

The product/substance has no endocrine disrupting properties.

12.7 Other adverse effects: None known.

### SECTION 13. DISPOSAL CONSIDERATIONS

#### 13.1 Waste treatment methods:

Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental regulations.

Contaminated packing: Do not reuse emptied containers.

### SECTION 14. TRANSPORT INFORMATION

This product is not classified as dangerous of transport.

|                             | ADR/RID      | IMDG/IMO     |
|-----------------------------|--------------|--------------|
| 14.1 UN number or ID number | Not relevant | Not relevant |
|                             |              |              |

| 14.2 UN proper shipping name            | Not relevant                             | Not relevant                             |
|---|--|--|
| 14.3 Transport hazard class(es)         | Not relevant                             | Not relevant                             |
| 14.4 Packing group                      | Not relevant                             | Not relevant                             |
| 14.5 Environmental hazards - MP<br>EmS: | No<br>Not relevant                       | No<br>Not relevant                       |
| Other informations                      | LQ: Not relevant<br>Tunnel: Not relevant | LQ: Not relevant<br>Tunnel: Not relevant |

14.6 Special precautions for user:

Not relevant.

### 14.7 Maritime transport in bulk according to IMO instruments:

Not relevant.

### SECTION 15. REGULATORY INFORMATION

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

**Sources:** Current ADR regulations 2024. Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013. Regulation (EU) 2016/425 of 9 March 2016 on personal protective equipment. Hazardous Waste (England and Wales) Regulations 2005 (as amended). EC regulation 1907/2006 (REACH) Directive 2000/532/EC. Seveso directive: 96/82/EC. EC regulation No 2020/878. CLP regulation No 1272/2008. REACH regulation 1907/2006. GB CLP.

### 15.2 Chemical safety assessment:

Not necessary.

### SECTION 16. OTHER INFORMATION

#### Additional information:

It is recommended to hand over this safety data sheet to the actual user of the product. Information in this safety data sheet cannot be used as a product specification.

The information in this safety data sheet applies only to this specific product (mentioned in section 1) and is not necessarily correct for use with other chemicals/products.



### Safety data sheet Example

Version 1.0 Effective date: 14-08-2024

#### Descriptions of possible used abbreviations:

BCF Bioconcentration factor. BOD Biochemical Oxygen Demand. CAS Chemical Abstracts Service (service that maintains the most comprehensive list of chemical substances).

COD Chemical oxygen demand.

DNEL Derived No-Effect Level.

EC50 Effective Concentration 50 %. The EC50 corresponds to the concentration of a tested substance causing 50 % changes in response (e.g. on growth) during a specified time interval.

IMDG International Maritime Dangerous Goods Code.

LC50 Lethal Concentration 50%: the LC50 corresponds to the concentration of a tested substance causing 50 % lethality during a specified time interval.

LD50 Lethal Dose 50 %: the LD50 corresponds to the dose of a tested substance causing 50 % lethality during a specified time interval.

log KOW n-Octanol/water.

MARPOL International Convention for the Prevention of Pollution from Ships (abbr. of "Marine Pollutant"). PBT Persistent, Bioaccumulative and Toxic.

PNEC Predicted No-Effect Concentration.

UN RTDG UN Recommendations on the Transport of Dangerous Good.

vPvB Very Persistent and very Bioaccumulative.

Validated by: SRS www.msds-eu.com